Ingredients in benaGene have been the subject of several clinical trials to reduce glucose. The patients at highest risk (diabetics) showed an average fasting glucose reduction of 23.7 +/- 3.4%. Not just for diabetics, however, glucose reduction was also seen in non-diabetics and animals during the trials. The ages tested ranged from 17 years old to 95 years old showing no side effects in the 30 to 45 day study. The results of these clinical trials can be seen in the following tables.
Maximal
Fasting Glucose
Age
Dose (mg)
Before
After
% Reduction
Side Effects
90
600
200
120
40.0%
None
17
600
287
230
19.9%
None
57
600
157
113
28.0%
None
45
600
226
201
11.1%
None
50
300
180
116
35.6%
None
15
300
245
104
57.6%
None
92
300
84
78
7.1%
None
23
200
200
180
10.0%
None
52
300
190
167
12.1%
None
70
200
183
167
8.7%
None
48
300
175
151
13.7%
None
45
900
294
215
26.9%
None
33
200
195
181
7.2%
None
48
400
195
162
16.9%
None
49
1,000
149
100
32.9%
None
32
300
224
198
11.6%
None
53
1,000
115
104
9.6%
None
95
300
180
116
35.6%
None
54
300
190
114
40.0%
None
50
600
230
106
53.9%
None
90
100
134
109
18.7%
None
Average 23.7%
Change in Glucose Uptake in blood serum for diabetic and normal patients are shown below. The increase in glucose uptake indicates a decrease in insulin resistance, and also leads to less glucose in the blood stream. Having less glucose available leads to lower rates of protein glycation. In diabetic patients, the increase in glucose uptake averaged 299%. In normal patients, the increase averaged 180%.
